Mill Capital Management’s Pfizer PFE Stock Holding History

Mill Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Sell	143,638 -10,227	-7%	-$268K	0.23%	47
2026 Q1	$4.32M	Sell	153,865 -4,400	-3%	-$117K	0.33%	43
2025 Q4	$3.94M	Hold	158,265	–	–	0.28%	43
2025 Q3	$4.03M	Sell	158,265 -12,637	-7%	-$312K	0.3%	44
2025 Q2	$4.14M	Sell	170,902 -5,350	-3%	-$125K	0.32%	40
2025 Q1	$4.47M	Sell	176,252 -8,653	-5%	-$226K	0.36%	39
2024 Q4	$4.91M	Sell	184,905 -5,259	-3%	-$143K	0.39%	38
2024 Q3	$5.5M	Sell	190,164 -5,127	-3%	-$150K	0.43%	37
2024 Q2	$5.46M	Sell	195,291 -7,679	-4%	-$211K	0.45%	38
2024 Q1	$5.63M	Sell	202,970 -2,000	-1%	-$55.5K	0.47%	38
2023 Q4	$5.9M	Sell	204,970 -3,576	-2%	-$108K	0.53%	38
2023 Q3	$6.92M	Sell	208,546 -953	-0.5%	-$33.7K	0.68%	37
2023 Q2	$7.68M	Buy	209,499 +7,277	+4%	+$283K	0.72%	37
2023 Q1	$8.25M	Sell	202,222 -8,915	-4%	-$385K	0.84%	34
2022 Q4	$10.8M	Hold	211,137	–	–	1.19%	30
2022 Q3	$9.24M	Sell	211,137 -303	-0.1%	-$14.7K	1.08%	27
2022 Q2	$11.1M	Hold	211,440	–	–	1.23%	27
2022 Q1	$10.9M	Sell	211,440 -2,340	-1%	-$121K	1.05%	32
2021 Q4	$12.6M	Buy	+213,780	New	+$10.6M	1.29%	23

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mill Capital Management's PFE Position: Q2 2026 in Review

Mill Capital Management reduced its Pfizer (PFE) stake by 6.6% in Q2 2026, selling an estimated $268K and leaving 143,638 shares worth $3.46M. The position accounts for 0.23% of the portfolio, ranked #47.

Mill Capital Management first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $12.6M in Q4 2021. 2,835 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Mill Capital Management held 143,638 shares of Pfizer worth $3.46M as of Q2 2026.
Mill Capital Management sold 10,227 Pfizer shares in Q2 2026, an estimated $268K.
Pfizer made up 0.23% of Mill Capital Management's portfolio in Q2 2026, its #47 holding.
Mill Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
Mill Capital Management's Pfizer position peaked at $12.6M in Q4 2021.
2,835 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Mill Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.